HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的是测试候选AIDS疫苗中DNA引发-VSV加强系统中的各种引发和加强方案。2007年6月，获得了30只动物，目的是比较VSV-Gstem（非复制型载体）和复制型VSV载体在用通过电穿孔递送的DNA致敏的动物中的加强效率。异源DNA/VSV免疫也与同源DNA进行了比较。 将动物分为5组，每组6只。 组1、2和3每30天接受3次DNA引发免疫。 第4和5组未接受初免免疫。 在第一次疫苗接种后5个月，组1和4接受VSV-Gstem加强，组2和5接受复制-VSV加强，组3接受DNA加强。 第3组在2008年2月获得了2次额外的增强，而其他4组将在2008年3月获得增强。 采集血样以监测这些动物的免疫反应。 细胞介导的免疫反应将持续到2008年7月。该计划已被惠氏疫苗终止。 目的是将研究转移到另一家疫苗公司。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose is to test various priming and boosting regimes in the DNA prime-VSV boosting systems in candidate AIDS vaccines. In June 2007, 30 animals were obtained with the intention of comparing boosting efficiency of VSV-Gstem, a non-replicating vector and replicating-VSV vectors in animals that were primed with DNA delivered via electroporation. Heterologous DNA/VSV immunizations were also compared with the homologous DNA. The animals were divided into 5 groups of 6 each. Groups 1, 2, & 3 received 3 DNA priming immunizations every 30 days. Groups 4 & 5 did not receive a priming immunization. At 5 month post first vaccination, groups 1 & 4 received a VSV-Gstem boosts, groups 2 & 5 received a replicating-VSV boost, and group 3 received a DNA boost. Group 3 received 2 additional boosts in February 2008, while the other 4 groups will receive boosts in March 2008. Blood samples have been collected in order to monitor the immune responses of these animals. The cell-mediated immune responses will be followed through July 2008. This program is being terminated by Wyeth Vaccines. The intention is to move the research to another vaccine company.